Everest Organics board to meet on May 29 to consider FY26 results
Everest Organics Limited will hold a board meeting on May 29, 2026, to approve audited standalone financial results for the quarter and year ended March 31, 2026. The board will also review the statutory auditor's draft report. The trading window remains closed until 48 hours post-results declaration.

*this image is generated using AI for illustrative purposes only.
Everest Organics Limited has informed the stock exchanges that its board of directors will meet on Friday, May 29, 2026. The meeting has been convened pursuant to Regulations 29 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Agenda for the Meeting
The primary agenda for the upcoming board meeting includes the consideration and approval of the audited standalone financial results of the company for the quarter and year ended March 31, 2026. Additionally, the directors will take note of the draft report of the statutory auditors for the financial year ending March 31, 2026.
Trading Window Closure
In accordance with regulatory requirements, the company had previously intimated that the trading window closure period commenced on April 01, 2026. This window shall remain closed until 48 hours after the declaration of the audited standalone financial results for the quarter and year ended March 31, 2026.
Key Meeting Details
| Detail | Information |
|---|---|
| Meeting Date | May 29, 2026 |
| Purpose | Consider Audited Financial Results for FY26 |
| Financial Year End | March 31, 2026 |
| Trading Window Closure | From April 01, 2026 |
The intimation regarding this board meeting is available on the company's official website and the website of the stock exchange where its shares are listed.
Historical Stock Returns for Everest Organics
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.87% | -3.68% | -11.18% | -42.57% | -42.14% | -25.49% |
How does Everest Organics Limited's revenue and profit growth for FY26 compare to its peers in the pharmaceutical and specialty chemicals sector?
Will the board consider announcing a dividend or any capital allocation strategy alongside the FY26 financial results approval?
Are there any pending regulatory inspections or compliance issues that could impact the auditor's report and overall financial health of the company?


































